Centrers for Disease Control and Prevention suggest that the more contagious subvariant BA.2 of omicron strain now makes up 72% of COVID-19 infections in the U.S. According to the data, the BA.2 is able to displace all other COVID-19 strains and its subvariants. Ali Mokdad, an epidemiologist at the Institute for Health Metrics and Evaluation in Washington state, estimates that the displacement might happen in the next two weeks. According to different sources, the BA.2 is from 30% to 80% more contagious than the BA.1. A top WHO official, Maria Van Kerkhove, describes BA.2 as the most transmissible version of the virus so far. 

Pectins are a major dietary nutrient source for the human gut microbiota. The prominent gut microbe Bacteroides thetaiotaomicron was recently shown to encode the founding member (BT1017) of a new family of pectin methylesterases essential for the metabolism of the complex pectin rhamnogalacturonan-II (RG-II). However, biochemical and structural knowledge of this family is lacking. Here, we showed that BT1017 is critical for the metabolism of an RG-II–derived oligosaccharide ΔBT1017oligoB generated by a BT1017 deletion mutant (ΔBT1017) during growth on carbohydrate extract from apple juice. Structural analyses of ΔBT1017oligoB using a combination of enzymatic, mass spectrometric, and NMR approaches revealed that it is a bimethylated nonaoligosaccharide (GlcA-β1,4-(2-O-Me-Xyl-α1,3)-Fuc-α1,4-(GalA-β1,3)-Rha-α1,3-Api-β1,2-(Araf-α1,3)-(GalA-α1,4)-GalA) containing components of the RG-II backbone and its side chains. We showed that the catalytic module of BT1017 adopts an α/β-hydrolase fold, consisting of a central twisted 10-stranded β-sheet sandwiched by several α-helices. This constitutes a new fold for pectin methylesterases, which are predominantly right-handed β-helical proteins. Bioinformatic analyses revealed that the family is dominated by sequences from prominent genera of the human gut microbiota, including Bacteroides and Prevotella. Our re-sults not only highlight the critical role played by this family of enzymes in pectin metabolism but also provide new insights into the molecular basis of the adaptation of B. thetaiotaomicron to the human gut.

Some cases of chylomicronemia are caused by autoantibodies against glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1), an endothelial cell protein that shuttles LPL to the capillary lumen. GPIHBP1 autoantibodies prevent binding and transport of LPL by GPIHBP1, thereby disrupting the lipolytic processing of triglyceride-rich lipoproteins. Here, we review the "GPIHBP1 autoantibody syndrome" and summarize clinical and laboratory findings in 22 patients. All patients had GPIHBP1 autoantibodies and chylomicronemia, but we did not find a correlation between triglyceride levels and autoantibody levels. Many of the patients had a history of pancreatitis, and most had clinical and/or serological evidence of autoimmune disease. IgA autoantibodies were present in all patients, and IgG4 autoantibodies were present in 19 of 22 patients. Patients with GPIHBP1 autoantibodies had low plasma LPL levels, consistent with impaired delivery of LPL into capillaries. Plasma levels of GPIHBP1, measured with a monoclonal antibody–based ELISA, were very low in 17 patients, reflecting the inability of the ELISA to detect GPIHBP1 in the presence of autoantibodies (immunoassay interference). However, GPIHBP1 levels were very high in five patients, indicating little capacity of their autoantibodies to interfere with the ELISA. Recently, several GPIHBP1 autoantibody syndrome patients were treated successfully with rituximab, resulting in the disappearance of GPIHBP1 autoantibodies and normalization of both plasma triglyceride and LPL levels. The GPIHBP1 autoantibody syndrome should be considered in any patient with newly acquired and unexplained chylomicronemia.

DOVER, DE (Dec. 17, 2021) – The Delaware Division of Public Health (DPH) today announced that it has confirmed the first four cases of the Omicron variant (B.1.1.529) among Delaware residents. The variant was detected today through routine sequencing of test specimens by the Delaware Public Health Laboratory. The four cases involve two adults in […]

Title: Pfizer Asks FDA to Approve Omicron-Specific Booster Shot
Category: Health News
Created: 8/22/2022 12:00:00 AM
Last Editorial Review: 8/23/2022 12:00:00 AM

A growing number of studies indicate Omicron is more resistant to current vaccines than previous Covid variants, though boosters seem to help. WSJ’s Daniela Hernandez gets an exclusive look inside a lab testing how antibodies interact with Omicron. Photo illustration: Tom Grillo

The Omicron variant caused more than 70% of new coronavirus cases in the U.S. registered the week ending Dec. 18, according to the Centers for Disease Control and Prevention. The surge comes as the holidays approach and some people reconsider travel plans. Photo: Jeenah Moon/Bloomberg

China got out ahead of the U.S. in shipping its Covid-19 vaccines around the world, but the Biden administration said it has donated more doses. WSJ examines how Omicron challenges both as they push for global influence. Photo: Rodrigo Sura/Esteban Biba/Shutterstock

A wave of Covid-19-related school staffing issues has led some states to take drastic steps to keep schools open, including enlisting state employees, retirees and National Guard members to fill in as substitute teachers. Photo: Marcio Jose Sanchez/Associated Press

Airlines scrapped more than 3,000 U.S. flights and delayed more than 5,000 on Monday. The new wave of cancellations and delays comes as the surge in Covid-19 infections in the U.S. has left the airline industry stretched thin. Photo: Chandan Khanna/AFP/Getty Images

China is enforcing a strict set of Covid-19 rules at the Winter Olympics to stop the fast-spreading Omicron variant. From a "closed-loop” system to a ban on shouting, WSJ explains how some of these restrictions will work, and why despite all efforts, an outbreak could still derail competitions. Photo: Fabrizio Bensch/Reuters

Scientists are using automation, real-time analysis and pooling data from around the world to rapidly identify and understand new coronavirus variants before the next one spreads widely. Photo Illustration: Sharon Shi

Over 3,000 flights were cancelled on the eve of Christmas and cancellations are expected to double as New Year approaches

The number of hospitalisations in 20 days since the Omicron variant was discovered was relatively lower than the pace observed during the Delta wave in Gauteng in South Africa

euromicron AG, a medium-sized technology group and specialist for networking business and production processes, has taken on Funkwerk AG, Kölleda, as a strategic anchor investor. Funkwerk AG is a leading provider of innovative communication, information and security systems and intends to acquire a total of up to around 28% of euromicron AG’s increased share capital following the implementation of the resolved capital measures.

Consolidated sales of EUR 146.7 million EBITDA (before IFRS 16) increased strongly by EUR 3.8 million to EUR 2.1 million Forecast for 2019 as a whole confirmed Working capital ratio declines by 2 percentage points to 10.6% euromicron AG, a medium-sized technology group and specialist for the digital networking of business and production processes, published its preliminary figures for the first half of 2019 today.

Final half-year figures equivalent to the published figures EUR 3.8 million increase in EBITDA (before IFRS 16) shows improved quality of the margin Forecast for 2019 as a whole confirmed euromicron AG, a medium-sized technology group and specialist for the digital networking of business and production processes, published its report for the first half of 2019 today.

euromicron AG, a medium-sized technology group and specialist for the digital support of business processes through secure infrastructures, is pooling its digital expertise at KORAMIS GmbH, the group subsidiary that specializes in cyber security and automation. With focus on digital platforms and services KORAMIS’ portfolio will also cover the areas Smart IoT, Smart Building as well as Data Management in the future. For this step the management of KORAMIS GmbH was extended by Andreas Schmidt.

euromicron AG, a medium-sized technology group and expert on the digital networking of business and production processes, has now fully placed the capital increase it resolved on July 10, 2019.

euromicron AG, a medium-sized technology group and expert on digital networking of business and production processes, held its Annual General Meeting 2019 in Frankfurt/Main on August 29, 2019. 42 percent of the share capital was represented. At the Annual General Meeting, the Executive Board reported on the operating performance in fiscal year 2018 and in the first half of 2019 and gave an outlook on the current fiscal year. One focus was on the implementation of the measures initiated to focus on and further develop the business model.

ssm euromicron GmbH, a system house subsidiary of euromicron AG, is involved in a project to provide the technical equipment for the new building for the Institute of Geosciences at Kiel’s Christian Albrechts University. The seven-story new building is part of a campus-wide modernization initiative that is one of the largest public high-rise projects in the federal state of Schleswig-Holstein.

Final numbers for the first nine months match previously published figures Development of consolidated sales due to order postponements behind plan EBITDA (before IFRS 16) of €2.0 million and so slightly up year over year Capital increase completed successfully in the third quarter of 2019 Guidance for the whole of 2019 adjusted

The Supervisory Board of euromicron AG (WKN A1K030) announced a new appointment and expansion of the Executive Board of euromicron AG today, thus initiating a first step for a new phase in the realignment of the Group. Effective January 1, 2020, Dr. Michael Hofer will be appointed Chief Financial Officer (CFO) and Dr. Andreas Schmid Chief Operations Officer (COO) on the Executive Board of euromicron AG.

Elevated levels of triglyceride-rich lipoproteins (TRLs), both fasting and postprandial, are associated with increased risk for atherosclerosis. However, guidelines for treatment are defined solely by fasting lipid levels, even though postprandial lipids may be more informative. In the postprandial state, circulating lipids consist of dietary fat transported from the intestine in chylomicrons (CMs; containing ApoB48) and fat transported from the liver in VLDL (containing ApoB100). Research into the roles of endogenous versus dietary fat has been hindered because of the difficulty in separating these particles by ultracentrifugation. CM fractions have considerable contamination from VLDL (purity, 10%). To separate CMs from VLDL, we produced polyclonal antibodies against ApoB100 and generated immunoaffinity columns. TRLs isolated by ultracentrifugation of plasma were applied to these columns, and highly purified CMs were collected (purity, 90–94%). Overall eight healthy unmedicated adult volunteers (BMI, 27.2 ± 1.4 kg/m²; fasting triacylglycerol, 102.6 ± 19.5 mg/dl) participated in a feeding study, which contained an oral stable-isotope tracer (1-¹³C acetate). We then used this technique on plasma samples freshly collected during an 8 h human feeding study from a subset of four subjects. We analyzed fractionated lipoproteins by Western blot, isolated and derivatized triacylglycerols, and calculated fractional de novo lipogenesis. The results demonstrated effective separation of postprandial lipoproteins and substantially improved purity compared with ultracentrifugation protocols, using the immunoaffinity method. This method can be used to better delineate the role of dietary sugar and fat on postprandial lipids in cardiovascular risk and explore the potential role of CM remnants in atherosclerosis.